Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more
Peplin's Positive Phase II AK Trial Results Published in JAAD read more
Positive Results for Peplin's First Phase III AK Trial read more
Peplin Results for the Quarter Ended 31 March 2009 read more

Dr. Pace has served as a member of our board of directors since June 2004. Since November 2007, Dr. Pace has been the Vice Chairman of Hunter Immunology Ltd., a development state biopharmaceutitical company. Dr. Pace also serves as a member of the board of directors of QRxPharma Ltd., a clinical-stage specialty pharmaceutical company, a position he has held since 2002. He is also a director of ResMed, Inc., a publicly-held medical device company, Transition Therapeutics Inc., a publicly-held biopharmaceutical company, Celsion Corporation, a publicly-held biotechnology company and Pacira Pharmaceuticals, Inc., a privately-held acute-care specialty pharmaceuticals company. From 2000 to 2002, Dr. Pace was Chairman and Chief Executive Officer of Waratah Pharmaceuticals Inc., a biopharmaceutical company. From 1995 to 2001, Dr. Pace was President and Chief Executive Officer of RTP Pharma Inc., a pharmaceutical company. From 1993 to 1994, he was the founding President and Chief Executive Officer of Transcend Therapeutics Inc. (formerly Free Radical Sciences Inc.), a biopharmaceutical company. From 1989 to 1993, Dr. Pace was Senior Vice President of Clintec International, Inc., a manufacturer of clinical nutritional products.
Dr. Pace received a B.S. with honors from the University of New South Wales and a Ph.D. from Massachusetts Institute of Technology.